Propanc Biopharma Inc PPCB

$2.87 -5.13 (-64.13%)

Valuation

Market cap
155,000
Revenue TTM
$0
Net income TTM
$-1,820,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.03

Trading

Volume
489,547
Avg volume
2,732
Day's range
$2.82 – $4.50
Shares out
19,000
Stochastic %K
94%
Beta
2.78
Analysts
Strong Buy
Price target
$12.50

Price

Company profile

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a resea...

Show more

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.

Industry
Biotechnology
Sector
Healthcare
Phone
61 3 9882 0780
Website
https://www.propanc.com
Address
302, 6 Butler Street, Camberwell, Australia

Latest news

Stocktwits

TraderBuckNKY Oct 2, 7:12 PM
$PPCB anybody concurring with this...?...
0 replies
strong_Dan Oct 2, 4:08 PM
$PPCB Since you liked it, here' some more (we become better investigators for our bright future ; only one rule: become capable to avoid trash/trashy moves and you're guaranteed to be with the rich--and also not subsidize leeches): check your broker's publised float for PPCB since it's officially calculated 8 days ago, some do not update (Trade Zero did for me) In August we' got hit by something else than expected, latest FORM 10-K says: "In August 2026, the Company issued an aggregate of 2,204,660 shares of its common stock as a result of the conversion of 150 shares of Series C Preferred stock." The September crash should have had been because: "In September 2026, the Company issued an aggregate of 328,000 shares of its common stock as a result of the conversion of 50 shares of Series C Preferred stock." Annnnnd: "As of September 23, 2026 there were 6,331,116 shares of Common Stock issued and outstanding" . That math does not include the 3.5M! =)) Total shares outstanding: 6.3M + 3.5M = 9.8M
0 replies
strong_Dan Oct 2, 3:03 PM
$PPCB Dumpster fire :)) Their AI just said : "During FY2026, $PPCB raised $7.5M in gross proceeds. Since June 30, the Company has received an additional $2M through its Series C facility, which the Company expects to support planned R&D activities," From WHO's money? From dilution since they have zero revenue. Dilution = they sell some paper [promises] to you and then take THE SAME paper and sell it to somebody else also. | Claiming that: don't worry, all of you are lucky! :)) And it's not even actually "TRUE", it's fraud. It's like this: FORM 10-K | For the fiscal year ended June 30, 2026 "Repurchase Plan Between July 2026 and August 2026, the Company repurchased 320,031 shares of its common stock under the Repurchase Plan for an aggregate purchase price of approximately $500,000, at an average purchase price of $1.56 per share." next paragraph: "Shares issued for services On July 24, 2026, the Company issued an aggregate of 3,500,000 shares of common stock to (..) directors (..).
0 replies
IR_propancbiopharma Oct 2, 2:17 PM
Advancing PRP into clinical development requires both scientific execution and capital to support it. During FY2026, $PPCB raised $7.5M in gross proceeds. Since June 30, the Company has received an additional $2M through its Series C facility, which the Company expects to support planned R&D activities, including PRP and Rec-PRP. As PRP advances toward Phase 1b, capital and clinical execution remain closely connected.
1 replies
CapnKrunch Oct 2, 1:46 PM
$PPCB markets ripping and this pig can’t hold a 0.5% gain on the day 😂 Hot garbage, trash management, FRAUD!
0 replies
Maxandbear Oct 2, 2:13 AM
$PPCB block bears
0 replies
IR_propancbiopharma Oct 1, 7:36 PM
PRP’s path to the clinic is no longer just a development plan. The infrastructure behind it is taking shape. $PPCB has established key relationships supporting Phase 1b, including Avance Clinical for clinical delivery, a specialized CDMO for GMP manufacturing, and FyoniBio for PRP’s PK assay. Clinical development requires multiple pieces to come together. For PRP, those pieces are now being put in place. The foundation for the next stage is being built now. $IONS $BEAM
1 replies
CapnKrunch Oct 1, 3:06 PM
$PPCB time to cut losses, this turd will be under .10 before doing a 20 for 1 reverse split. Trash PR, they will be buried before any meaningful cancer treatment.
0 replies